Fortis Healthcare Limited has informed the Exchange about Appointment of Cost Auditor for Financial Year 2025-26 and Appointment of Secretarial Auditors for a term of Five (5) years.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditors B S R & Co. LLP issuing a clean (unmodified) opinion. A final dividend of ₹1 per share (10% of face value) has been recommended for FY25, subject to shareholder approval. The company appointed M/s Jitender, Navneet & Co. as Cost Auditor for FY26 and M/s Neelam Gupta & Associates as Secretarial Auditor for a 5-year term (April 2025 to March 2030). On the numbers, standalone FY25 revenue from operations grew to ₹1,44,589 lacs from ₹1,18,141 lacs a year ago, but net profit fell sharply to ₹6,379 lacs from ₹19,945 lacs, dragged down by an exceptional loss of ₹11,514 lacs (impairment of investments in subsidiaries). Q4 FY25 swung to a standalone net loss of ₹4,223 lacs versus a profit of ₹6,833 lacs in Q4 FY24, again on a ₹5,242 lac exceptional impairment.
Shareholders get a modest ₹1 per share dividend, but the sharp drop in FY25 net profit and the Q4 loss (driven by subsidiary investment impairments) may weigh on near-term sentiment. The clean audit opinion and new long-term auditor appointments signal governance continuity rather than concern.